It has been suggested that MK3 is a major factor in the development of liver fibrosis, and β-sitosterol could be used to target MK3, thereby reducing the phosphorylation of IκB and the activation of the NK-κB pathway (Figure 9). This evidence concerns the gene MAPKAPK3 and Hepatic fibrosis.